Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab
Abstract Purpose Early evaluation of the efficacy of first-line chemotherapy combined with bevacizumab in patients with colorectal cancer liver metastasis (CRLM) remains challenging. This study used 2-month post-chemotherapy spectral computed tomography (CT) to predict the overall survival (OS) and...
Main Authors: | Shenglin Li, Long Yuan, Mengying Yue, Yuan Xu, Suwei Liu, Feng Wang, Xiaoqin Liu, Fengyan Wang, Juan Deng, Qiu Sun, Xianwang Liu, Caiqiang Xue, Ting Lu, Wenjuan Zhang, Junlin Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | Cancer Imaging |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40644-023-00547-w |
Similar Items
-
FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis
by: M. Yu. Fedyanin, et al.
Published: (2020-12-01) -
Real-world uptake and effectiveness of triplet versus doublet chemotherapy with bevacizumab in patients with metastatic colorectal cancer in the United States
by: W.J. Chapin, MD, MSCE, et al.
Published: (2024-09-01) -
FOLFOXIRI in patients with colon cancer and isolated non-resectable liver metastases: phase II prospective non-randomized single-center study
by: M. Yu. Fedyanin, et al.
Published: (2019-11-01) -
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAF V600E mutated colorectal cancer—results from the FIRE‐4.5 study
by: Susanne Klein‐Scory, et al.
Published: (2025-02-01) -
FOLFOXIRI plus cetuximab as conversion therapy for unresectable RAS/BRAF wild-type left-sided colorectal cancer with liver-limited metastases: a prospective dual-center pilot study
by: Wenwei Yang, et al.
Published: (2024-04-01)